Daxor announces the expansion of blood volume analysis in three new hospitals through new analyzer purchases, and the utilization of Daxor’s ezBVA Lab service. These new acquisitions further fuel BVA sales growth and underscore its clinical relevance. New client and services wins include: BVA analyzer purchase at a 735-bed non-profit, tertiary, research and academic medical center located in northern New Jersey. Daxor’s ezBVA Lab service extended to a regional academic medical center, Level I adult trauma center in Ohio. Daxor’s ezBVA Lab service extended to an academic, integrated health system located in South Carolina.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DXR:
- Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
- Daxor announces new data on benefits of BVA
- Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients
- Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
- Daxor announces two significant customer transactions with BVA-100
